Citations

Mayo Clinic

Clear

3207 citation(s) found for "Vo, Mary".

P3‐122: High plasma Aβ40 levels are associated with incident Cognitive Impairment not Demented (CIND) and dementia cases in persons of Mexican ancestry (SALSA study)
Graff‐Radford, Neill R., Lucas, John A. , Younkin, Linda H., Moore, Kari, Younkin, Steven G. , Haan, Mary N. , Graff‐Radford, Neill R., Crook, Julia E.

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_12 | Pages: No page available

10.1016/j.jalz.2009.04.1097 Get It

Pleural Effusions: Etiology, Diagnosis, and Management
Cordes, Mary Ellen

The Journal of Continuing Education in Nursing | June 18, 2009 | Volume: 40 | Issue: 6 | Pages: 248-249

10.3928/00220124-20090522-03 | PMID 19639912 Get It

This column describes the etiology, diagnosis, and management of pleural effusions. J Contin Educ Nurs 2009;40(6):248–249.
The Biography of Mary E. O'Sullivan: An Early American Headache Specialist
Jerath, NU, Newman, JS, Boes, CJ

Cephalalgia | April 9, 2009 | Volume: 29 | Issue: 10 | Pages: 1028-1033

10.1111/j.1468-2982.2009.01845.x | PMID 19735530 Get It

The aim of this study was to review the life of Mary E. O'Sullivan and to summarize her important contributions to the study of migraine. Mary E. O'Sullivan underwent extensive training to become a neurologist at a time when only 5% of women in America were physicians. She published five papers on migraine. In a 1936 Journal of the American Medical Association article, she described a patient with ergotamine overuse headache and recommended that daily doses of oral ergotamine should be avoided. Three years later she described migraine as a ‘complex’ syndrome with multiple causes and multiple cures. Mary E. O'Sullivan, an ambitious female headache specialist of the 1930s, was an early advocate of the use of ergotamine to treat migraine, yet she was one of the first to report ergotamine overuse headache. Although her life was short, her research, knowledge and ambition at a time when women had limited opportunities in medicine have left a mark.
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Lara, Primo N. , Natale, Ronald B., Crowley, John, Lenz, Heinz Josef, Carleton, Jane E., Jett, James R., Langer, Corey J. , Kuebler, J. Philip , Dakhil, Shaker R. , Chansky, Kari, Gandara, David R. , Redman, Mary W. , Carleton, Jane E., Gandara, David

Journal of Clinical Oncology | April 7, 2009 | Volume: 27 | Issue: 15 | Pages: 2530-2535

10.1200/jco.2008.20.1061 | PMID 19349543 Get It

Purpose Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC. Patients and Methods Patients were randomly assigned to IP (irinotecan 60 mg/m2 on days 1, 8, and 15; cisplatin 60 mg/m2 day 1, every 4 weeks) or EP (etoposide 100 mg/m2 on days 1 through 3; cisplatin 80 mg/m2 day 1, every 3 weeks). Blood specimens for genomic DNA analysis were collected before random assignment in 169 patients. Results Of 671 patients, 651 were eligible (324 and 327 patients in the IP and EP arms, respectively). Response rates with IP and EP were 60% and 57%, respectively (P = .56). Median progression-free survival for IP and EP was 5.8 and 5.2 months, respectively (P = .07). Median overall survival for IP and EP was 9.9 and 9.1 months, respectively (P = .71). Severe diarrhea was more common with IP (19% v 3%); severe neutropenia and thrombocytopenia were higher with EP versus IP (68% v 33% and 15% v 4%, respectively). PG analysis showed that ABCB1 (C3435T)T/T (membrane transport) was associated with IP-related diarrhea; UGT1A1 (G-3156A)A/A (drug metabolism) was associated with IP-related neutropenia. Conclusion This large North American trial failed to confirm the previously reported survival benefit observed with IP in Japanese patients. Both regimens produced comparable efficacy, with less hematologic and greater gastrointestinal toxicity with IP. These results emphasize the potential importance of PG in interpreting trials of cancer therapy.
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study
Song, Honglin , Ramus, Susan J. , Kjær, Susanne K. , DiCioccio, Richard A., Chenevix‐Trench, Georgia , Pearce, Celeste Leigh, Høgdall, Estrid , Whittemore, Alice S. , McGuire, Valerie , Høgdall, Claus , Blaakær, Jan , Wu, Anna H. , Berg, David J. Van Den, Menon, Usha , Jacobs, Ian , Webb, Penny M., Beesley, Jonathan, Chen, Xiaoqing, Group, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study, Rossing, Mary Anne, Chang‐Claude, Jenny , Wang‐Gohrke, Shan , Goodman, Marc T. , Lurie, Galina, Thompson, Pamela J., Carney, Michael E., Ness, Roberta B., Moysich, Kirsten B., Goode, Ellen L. , Vierkant, Robert A. , Cunningham, Julie M. , Anderson, S. Keith , Schildkraut, Joellen M. , Iversen, Edwin S., Moorman, Patricia G. , García‐Closas, Montserrat , Lissowska, Jolanta , Brinton, Louise A. , Ponder, Bruce A.J., Easton, Douglas F. , Gayther, Simon A. , Pharoah, Paul D.P., Webb, Penelope M. , Bowtell, David D.L. , Stram, Daniel O. , Gentry‐Maharaj, Aleksandra , Webb, Penny M., Chen, Xiaoqing, Group, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study, Doherty, Jennifer A. , Berchuck, Andrew , Chanock, Stephen Jacob , Anton‐Culver, Hoda , Ziogas, Argyrios , Brewster, Wendy R. , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Human Molecular Genetics | March 20, 2009 | Volume: 18 | Issue: 12 | Pages: 2297-2304

10.1093/hmg/ddp138 | PMID 19304784 Get It

Crohn's Disease and Ulcerative Colitis
Twedell, Diane, Dettinger, Margaret, Matzke, Mary, McKay, K., Sizer, Rowena, Thoreson, Michelle, Wrobleski, Diane M., Twedell, Diane

The Journal of Continuing Education in Nursing | March 11, 2009 | Volume: 39 | Issue: 4 | Pages: 151-152

10.3928/00220124-20080401-04 | PMID 18429367 Get It

This column discusses the prevalence, symptoms, and treatment of Crohn's disease and ulcerative colitis and the role nurses play for these patients. J Contin Educ Nurs 2008;39(4):151–152.
Does Low-dose Droperidol Administration Increase the Risk of Drug-induced QT Prolongation and Torsade de Pointes in the General Surgical Population?
Nuttall, Gregory A. , Eckerman, Karen M., Jacob, Kelly A., Pawlaski, Erin M., Wigersma, Susan K., Marienau, Mary E. Shirk, Oliver, William C., Narr, Bradly J., Ackerman, Michael J.

Anesthesiology | March 4, 2009 | Volume: 107 | Issue: 4 | Pages: 531-536

10.1097/01.anes.0000281893.39781.64 | PMID 17893447 Get It

Background The US Food and Drug Administration issued a black box warning regarding the use of droperidol and the potential for torsade de pointes (TdP). Methods The primary objective of this retrospective study was to determine whether low-dose droperidol administration increased the incidence of TdP in the general surgical population during a 3-yr time period before and after the Food and Drug Administration black box warning. A random sample of 150 surgical patients during each time interval was selected to estimate the droperidol use for each time period. Results During the time period before the black box warning (July 1, 1998 to June 30, 2001), 2,321/139,932 patients (1.66%) had QT prolongation, TdP, or death within 48 h after surgery. We could identify no patients who clearly developed TdP before the black box warning. There was one patient for whom the cause of death could not positively be ruled out as due to TdP. In the time period after the black box warning (July 1, 2002 to June 30, 2005), 2,207 patients (1.46%) had documented QT prolongation, TdP, or death within 48 h after surgery, including only two cases (<0.1%) of TdP. The incidence of droperidol exposure was approximately 12% (exact 95% confidence interval, 7.3-18.3%) before the black box warning and 0% after placement of the black box warning on droperidol. Therefore, we estimate that approximately 16,791 patients (95% confidence interval, 10,173-25,607) were exposed to droperidol, none of whom experienced documented TdP. Conclusions This indicates that the Food and Drug Administration black box warning for low dose droperidol is excessive and unnecessary.
A Metric to Evaluate the Comparative Performance of an Institution's Graduate Medical Education Program
Murray, Peter M. , Valdivia, Jennifer H., Berquist, Mary R.

Academic Medicine | January 23, 2009 | Volume: 84 | Issue: 2 | Pages: 212-219

10.1097/acm.0b013e3181939705 | PMID 19174668 Get It

Abstract The economics of medicine have drastically changed during the past quarter century. Institutions may be faced with difficult decisions concerning graduate medical education (GME), particularly as it relates to the growth of existing programs and the creation of new programs. The authors describe a tool that they developed that can consistently measure the value of individual training programs while aligning with an institution's strategic priorities. This tool, the assessment metric scorecard, permits the annual prioritization of GME programs by the leadership of Mayo Clinic, Jacksonville, Florida. The scorecard also provides valuable data regarding the strengths and weaknesses of individual programs. The metric seeks to evaluate GME programs on the basis of four broad areas: Research, Teaching, Patient Service, and a General category. The assessment metric scorecard has been used since 2004; this article reports on its use for the academic years 2004–2005 and 2005–2006. The scorecard has proved to be a helpful tool for the yearly evaluation and prioritization of GME programs at the authors' institution. The overall mean score of the GME programs increased, which suggests a positive trend. This scorecard is flexible; modifications of the relative weights of the metrics can be made to align it with the strategic priorities of other institutions. The resources necessary to implement the scorecard are minimal.
Bone Structure at the Distal Radius During Adolescent Growth
Kirmani, Salman , Christen, D. K. , Lenthe, Harry van , Bouxsein, Mary , McCready, Louise K., Melton, L. Joseph, Riggs, B. Lawrence, Amin, Shreyasee , Müller, Ralph , Khosla, Sundeep , Fischer, Philip R. , Khosla, Sundeep

Journal of Bone and Mineral Research | December 29, 2008 | Volume: 24 | Issue: 6 | Pages: 1033-1042

10.1359/jbmr.081255 | PMID 19113916 Get It

Abstract The incidence of distal forearm fractures peaks during the adolescent growth spurt, but the structural basis for this is unclear. Thus, we studied healthy 6- to 21-yr-old girls (n = 66) and boys (n = 61) using high-resolution pQCT (voxel size, 82 μm) at the distal radius. Subjects were classified into five groups by bone-age: group I (prepuberty, 6–8 yr), group II (early puberty, 9–11 yr), group III (midpuberty, 12–14 yr), group IV (late puberty, 15–17 yr), and group V (postpuberty, 18–21 yr). Compared with group I, trabecular parameters (bone volume fraction, trabecular number, and thickness) did not change in girls but increased in boys from late puberty onward. Cortical thickness and density decreased from pre- to midpuberty in girls but were unchanged in boys, before rising to higher levels at the end of puberty in both sexes. Total bone strength, assessed using microfinite element models, increased linearly across bone age groups in both sexes, with boys showing greater bone strength than girls after midpuberty. The proportion of load borne by cortical bone, and the ratio of cortical to trabecular bone volume, decreased transiently during mid- to late puberty in both sexes, with apparent cortical porosity peaking during this time. This mirrors the incidence of distal forearm fractures in prior studies. We conclude that regional deficits in cortical bone may underlie the adolescent peak in forearm fractures. Whether these deficits are more severe in children who sustain forearm fractures or persist into later life warrants further study.